Sensorion’s SENS-111 fails to meet primary endpoint in AUV trial

analysis 2
The SENS-111 Phase IIb trial had three parallel arms and evaluated the efficacy and safety of SENS-111 histamine H4 receptor antagonist. Credit: kkolosov/ Pixabay.